Table 2 Summary of best overall response in SAGC and GC groups

From: Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trial

Efficacya

SAGC group (n = 37)

GC group (n = 34)

pc

Best overall responseb

  

0.033

 Partial response

19 (51.4%)

10 (29.4%)

 

 Stable disease

16 (43.2%)

19 (55.9%)

 

 Progressive disease

2 (5.4%)

5 (14.7%)

 

Objective response rate

51.4% (34.4%, 68.1%)

29.4% (15.1%, 47.5%)

 

Disease control rate

94.6% (81.8%,99.3%)

85.3% (68.9%,95.0%)

 

Median time to onset of response, months

2.5 (1.7, 3.6)

3.0 (2.7, 4.0)

 

Median duration of response, months

9.1 (4.9, NA)

3.4 (2, NA)

 
  1. aData are shown as n (%) and median (IQR).
  2. bPer mRECIST.
  3. cTwo-sided Fisher exact test for objective response rate.
Back to article page